People don't care about these announcements. Data drives...

People don't care about these announcements. Data drives commercial outcomes, and that's what people should be focused on.

Phase 1 is a critical time to evaluate the efficacy of a compound. Here is an example of a strong OV therapy that is on the path to approval for a single indication. Phase 1 data of CG0070 demonstrates complete repsonse rates in 48.6% of all patients, 63.6% in multidose cohorts and 81.8% in patients with borderline to high retinoblastoma phosphorylation. Wait til you see what lifting the dose did for efficacy...



They completed this study in 2012. It is now 2024 and they are still conducting studies, with some incredible data supporting efficacy not limited to this.



With investigational new drugs like this as the benchmark, maybe people are starting to realise that an oncology company in Australia with a failed P2 drug and a P1 oncolytic viral therapy that has so far demonstrated inter- and intra-individual inconsistency and little to no efficacy in >90% of patients (that also forms the backbone of three clinical programs) may not be worth $600M AUD. Since cholangiocarcinoma is rare and OV therapy market is extremely small, maybe investors are starting to think there is not much upside from $600M or maybe that there is just a lot of risk. Many lines of evidence support my contention that IMU is very high risk. I can understand selling until ~2c.

Treating cancer is easy, the more cytotoxic drug you give to humans always means better outcomes - SMH.



Patiently awaiting more data to analyse.

Global OV market averaged off data I could find